Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × HCC × lenvatinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Hepatocellular 114 Cholangiocarcinoma 24 Carcinoma, Renal Cell 19 Liver Neoplasms 12 Stomach Neoplasms 10 Biliary Tract Neoplasms 10 Thyroid Neoplasms 8 Breast Neoplasms 8 Neoplasms 7 Endometrial Neoplasms 7 Recurrence 6 Neuroendocrine Tumors 5 Neoplasm Metastasis 5 Melanoma 5 Uterine Cervical Neoplasms 4 Thyroid Carcinoma, Anaplastic 4 Thyroid Cancer, Papillary 3 Pancreatic Neoplasms 3 Ovarian Neoplasms 3 Liver Diseases 3 Cirrhosis, Familial, with Pulmonary Hypertension 3 Carcinoma, Adenoid Cystic 3 Brain Neoplasms 3 Advanced Biliary Tract Cancer 3 Adenocarcinoma, Follicular 3 Adenocarcinoma 3 Uveal Melanoma 2 Squamous Cell Carcinoma of Head and Neck 2 Small Cell Lung Carcinoma 2 Sarcoma 2

Interventions

Sorafenib 2 nimotuzumab 1 lenvatinib 1 atezolizumab 1 Stents 1 Radiotherapy 1 Radiosurgery 1 Radiofrequency Ablation 1 Immune Checkpoint Inhibitors 1 Hematologic Tests 1 Ethiodized Oil 1 Bevacizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05873244 2025-03-21

CXD101 in Immunotherapy-related Liver Cancer

Chinese University of Hong Kong

Phase 2 Recruiting

HCC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡